Overall, this study delineates a key signaling axis governing the crosstalk between CAFs and ccRCC tumor cells, highlighting FGF7 as a promising therapeutic target of ccRCC. This evidence concerns the gene FGF7 and nonpapillary renal cell carcinoma.